MediciNova Inc (MNOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MediciNova Inc (MNOV) has a cash flow conversion efficiency ratio of -0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.70 Million) by net assets ($43.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MNOV market cap overview for the company's overall valuation and market capitalisation.
MediciNova Inc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how MediciNova Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MediciNova Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MediciNova Inc ranked by their cash flow conversion efficiency. Explore MediciNova Inc (MNOV) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hennessy Ad
NASDAQ:HNNA
|
0.023x |
|
Thryv Holdings Inc
NASDAQ:THRY
|
0.101x |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
0.079x |
|
Many Peaks Minerals Ltd
AU:MPK
|
-0.020x |
|
Ybox Real Estate Ltd
TA:YBOX
|
-0.067x |
|
Cell Biotech Co. Ltd
KQ:049960
|
0.033x |
|
Columbus Acquisition Corp Ordinary Shares
NASDAQ:COLA
|
-0.002x |
|
Gopeng Bhd
KLSE:2135
|
-0.469x |
Annual Cash Flow Conversion Efficiency for MediciNova Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of MediciNova Inc from 2003 to 2024. View MNOV live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.50 Million | $-10.64 Million | -0.203x | -70.16% |
| 2023-12-31 | $62.38 Million | $-7.43 Million | -0.119x | +35.19% |
| 2022-12-31 | $70.24 Million | $-12.91 Million | -0.184x | -63.95% |
| 2021-12-31 | $83.68 Million | $-9.38 Million | -0.112x | +26.13% |
| 2020-12-31 | $71.33 Million | $-10.83 Million | -0.152x | -24.58% |
| 2019-12-31 | $74.89 Million | $-9.12 Million | -0.122x | +2.27% |
| 2018-12-31 | $73.11 Million | $-9.11 Million | -0.125x | +30.42% |
| 2017-12-31 | $38.64 Million | $-6.92 Million | -0.179x | +5.48% |
| 2016-12-31 | $34.53 Million | $-6.55 Million | -0.190x | +13.19% |
| 2015-12-31 | $32.75 Million | $-7.15 Million | -0.218x | -688.65% |
| 2014-12-31 | $22.01 Million | $816.53K | 0.037x | +108.86% |
| 2013-12-31 | $25.43 Million | $-10.65 Million | -0.419x | +47.48% |
| 2012-12-31 | $14.88 Million | $-11.86 Million | -0.797x | -40.78% |
| 2011-12-31 | $23.50 Million | $-13.31 Million | -0.566x | +20.94% |
| 2010-12-31 | $24.70 Million | $-17.70 Million | -0.716x | -68.48% |
| 2009-12-31 | $40.01 Million | $-17.01 Million | -0.425x | +3.26% |
| 2008-12-31 | $48.04 Million | $-21.12 Million | -0.440x | +33.24% |
| 2007-12-31 | $66.61 Million | $-43.86 Million | -0.658x | -95.22% |
| 2006-12-31 | $100.98 Million | $-34.06 Million | -0.337x | -100.04% |
| 2005-12-31 | $135.71 Million | $-22.88 Million | -0.169x | +90.45% |
| 2004-12-31 | $7.67 Million | $-13.55 Million | -1.766x | -36.09% |
| 2003-12-31 | $4.57 Million | $-5.93 Million | -1.298x | -- |
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more